Enanta Pharmaceuticals Stock Forecast, Price & News

Enanta Pharmaceuticals (NASDAQ:ENTA) Frequently Asked Questions

Is Enanta Pharmaceuticals a buy right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Enanta Pharmaceuticals in the last year. There are currently 4 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Enanta Pharmaceuticals stock.
View analyst ratings for Enanta Pharmaceuticals or view top-rated stocks.

How has Enanta Pharmaceuticals' stock price been impacted by COVID-19?

Enanta Pharmaceuticals' stock was trading at $52.92 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ENTA stock has increased by 41.4% and is now trading at $74.81.
View which stocks have been most impacted by COVID-19.

Are investors shorting Enanta Pharmaceuticals?

Enanta Pharmaceuticals saw a decrease in short interest in the month of November. As of November 15th, there was short interest totaling 681,000 shares, a decrease of 36.9% from the October 31st total of 1,080,000 shares. Based on an average daily trading volume, of 168,400 shares, the days-to-cover ratio is presently 4.0 days. Approximately 3.8% of the company's shares are sold short.
View Enanta Pharmaceuticals' Short Interest.

When is Enanta Pharmaceuticals' next earnings date?

Enanta Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, February 14th 2022.
View our earnings forecast for Enanta Pharmaceuticals.

How were Enanta Pharmaceuticals' earnings last quarter?

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) posted its quarterly earnings results on Monday, November, 22nd. The biotechnology company reported ($1.22) EPS for the quarter, beating analysts' consensus estimates of ($1.31) by $0.09. The biotechnology company had revenue of $23.58 million for the quarter, compared to analyst estimates of $35.65 million. Enanta Pharmaceuticals had a negative trailing twelve-month return on equity of 18.53% and a negative net margin of 81.38%. During the same quarter in the prior year, the business posted ($0.55) earnings per share.
View Enanta Pharmaceuticals' earnings history.

What price target have analysts set for ENTA?

8 analysts have issued 12-month price targets for Enanta Pharmaceuticals' shares. Their forecasts range from $55.00 to $130.00. On average, they anticipate Enanta Pharmaceuticals' share price to reach $90.88 in the next year. This suggests a possible upside of 21.5% from the stock's current price.
View analysts' price targets for Enanta Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are Enanta Pharmaceuticals' key executives?

Enanta Pharmaceuticals' management team includes the following people:

• Jay R. Luly, President, Chief Executive Officer & Director
• Paul J. Mellett, CFO & Senior VP-Finance & Administration
• Yat Sun Or, CSO, Senior Vice President-Research & Development
• Nathalie Adda, Chief Medical Officer & Senior Vice President (LinkedIn Profile)
• Nathaniel S. Gardiner, Secretary, Senior Vice President & General Counsel

What is Jay R. Luly's approval rating as Enanta Pharmaceuticals' CEO?

3 employees have rated Enanta Pharmaceuticals CEO Jay R. Luly on Glassdoor.com. Jay R. Luly has an approval rating of 100% among Enanta Pharmaceuticals' employees. This puts Jay R. Luly in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Enanta Pharmaceuticals' key competitors?

Some companies that are related to Enanta Pharmaceuticals include BridgeBio Pharma (BBIO), Blueprint Medicines (BPMC), HUTCHMED (HCM), Ultragenyx Pharmaceutical (RARE), Cerevel Therapeutics (CERE), Perrigo (PRGO), Ionis Pharmaceuticals (IONS), Allakos (ALLK), I-Mab (IMAB), Arvinas (ARVN), Apellis Pharmaceuticals (APLS), Alkermes (ALKS), Karuna Therapeutics (KRTX), ACADIA Pharmaceuticals (ACAD) and Zentalis Pharmaceuticals (ZNTL).
View all of ENTA's competitors.

What other stocks do shareholders of Enanta Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Enanta Pharmaceuticals investors own include Cronos Group (CRON), Dollar Tree (DLTR), AbbVie (ABBV), Gilead Sciences (GILD), Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), Netflix (NFLX), GW Pharmaceuticals (GWPH), Micron Technology (MU) and Zoetis (ZTS).

What is Enanta Pharmaceuticals' stock symbol?

Enanta Pharmaceuticals trades on the NASDAQ under the ticker symbol "ENTA."

Who are Enanta Pharmaceuticals' major shareholders?

Enanta Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (17.78%), First Manhattan Co. (4.80%), Krensavage Asset Management LLC (4.63%), Renaissance Technologies LLC (3.74%), Dimensional Fund Advisors LP (3.02%) and Geode Capital Management LLC (1.65%). Company insiders that own Enanta Pharmaceuticals stock include Jay R Luly, Nathalie Adda and Paul J Mellett.
View institutional ownership trends for Enanta Pharmaceuticals.

Which major investors are selling Enanta Pharmaceuticals stock?

ENTA stock was sold by a variety of institutional investors in the last quarter, including Invesco Ltd., Millennium Management LLC, BlackRock Inc., Tudor Investment Corp Et Al, Renaissance Technologies LLC, Goldman Sachs Group Inc., Dimensional Fund Advisors LP, and South Dakota Investment Council. Company insiders that have sold Enanta Pharmaceuticals company stock in the last year include Jay R Luly, Nathalie Adda, and Paul J Mellett.
View insider buying and selling activity for Enanta Pharmaceuticals or view top insider-selling stocks.

Which major investors are buying Enanta Pharmaceuticals stock?

ENTA stock was purchased by a variety of institutional investors in the last quarter, including First Manhattan Co., Assenagon Asset Management S.A., Portland Global Advisors LLC, UBS Group AG, TD Asset Management Inc., Citadel Advisors LLC, Voloridge Investment Management LLC, and Barclays PLC.
View insider buying and selling activity for Enanta Pharmaceuticals or or view top insider-buying stocks.

How do I buy shares of Enanta Pharmaceuticals?

Shares of ENTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Enanta Pharmaceuticals' stock price today?

One share of ENTA stock can currently be purchased for approximately $74.81.

How much money does Enanta Pharmaceuticals make?

Enanta Pharmaceuticals has a market capitalization of $1.52 billion and generates $97.07 million in revenue each year. The biotechnology company earns $-79 million in net income (profit) each year or ($3.91) on an earnings per share basis.

How many employees does Enanta Pharmaceuticals have?

Enanta Pharmaceuticals employs 141 workers across the globe.

What is Enanta Pharmaceuticals' official website?

The official website for Enanta Pharmaceuticals is www.enanta.com.

Where are Enanta Pharmaceuticals' headquarters?

Enanta Pharmaceuticals is headquartered at 500 ARSENAL STREET, WATERTOWN MA, 02472.

How can I contact Enanta Pharmaceuticals?

Enanta Pharmaceuticals' mailing address is 500 ARSENAL STREET, WATERTOWN MA, 02472. The biotechnology company can be reached via phone at (617) 607-0800, via email at [email protected], or via fax at 617-607-0530.